Document Detail


A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics.
MedLine Citation:
PMID:  23138100     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: We sought to assess the benefits, risks, and personal utility of factor V Leiden mutation testing to improve pregnancy outcomes and to assess the utility of decision-analytic modeling for complex outcomes in genomics.
METHODS: We developed a model to evaluate factor V Leiden testing among women with a history of recurrent pregnancy loss, including heparin therapy during pregnancy in mutation-positive women. Outcomes included venous thromboembolism, major bleeds, pregnancy loss, maternal mortality, and quality-adjusted life-years.
RESULTS: Factor V Leiden testing in a hypothetical cohort of 10,000 women led to 7 fewer venous thromboembolic events, 90 fewer pregnancy losses, and an increase of 17 major bleeding events. Small improvements in quality-adjusted life-years were largely attributable to reduced mortality but also to improvements in health-related quality of life. However, sensitivity analyses indicate large variance in results due to data uncertainty. Furthermore, the complexity of outcomes limited our ability to fully capture the repercussions of testing in the quality-adjusted life-year measure.
CONCLUSION: Factor V Leiden testing involves tradeoffs between clinical and personal utility, and additional effectiveness data are needed for heparin use to prevent pregnancy loss. Decision-analytic methods offer somewhat limited value in assessing these tradeoffs, suggesting that evaluation of complex outcomes will require novel approaches to appropriately capture patient-centered outcomes.Genet Med 2013:15(5):374-381.
Authors:
Preeti S Bajaj; David L Veenstra
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.     Date:  2012-11-08
Journal Detail:
Title:  Genetics in medicine : official journal of the American College of Medical Genetics     Volume:  15     ISSN:  1530-0366     ISO Abbreviation:  Genet. Med.     Publication Date:  2013 May 
Date Detail:
Created Date:  2013-05-07     Completed Date:  2013-10-22     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  9815831     Medline TA:  Genet Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  374-81     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Cost-Benefit Analysis
Decision Support Techniques
Decision Trees
Factor V / genetics*
Female
Genetic Testing* / economics
Genomics / economics,  methods
Humans
Mutation
Pregnancy
Pregnancy Outcome* / economics
Quality-Adjusted Life Years
United States
Grant Support
ID/Acronym/Agency:
1U18GD000005/GD/OGDP CDC HHS
Chemical
Reg. No./Substance:
0/factor V Leiden; 9001-24-5/Factor V
Comments/Corrections
Comment In:
Genet Med. 2013 May;15(5):335-7   [PMID:  23448720 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Population genetic data of 30 autosomal indels in Central Spain and the Basque Country populations.
Next Document:  Rapid diversification in Australia and two dispersals out of Australia in the globally distributed b...